Role of leukocyte immunoglobulin G receptors in vaccine-induced immunity to Streptococcus pneumoniae

Journal of Infectious Diseases

Volumn 187, Issue 11, 2003, Pages 1686-1693

  Saeland, Eirikur ^a   Leusen, Jeanette H W ^a   Vidarsson, Gestur ^a   Kuis, Wietse ^a   Sanders, Elisabeth A M ^a   Jonsdottir, Ingileif ^c   Van De Winkel, Jan G J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GENMAB   (Netherlands)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 3; FC RECEPTOR; FC RECEPTOR 1; FC RECEPTOR 3; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 TETANUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CD11B ANTIGEN; COBROTOXIN; SNAKE VENOM; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFECTION RESISTANCE; LEUKOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TITRIMETRY; VACCINATION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PHAGOCYTOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; COBRA VENOMS; LEUKOCYTES; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECEPTORS, IGG; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0038540670     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375276     Document Type: Article

References (51)

1. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3:171-96.
2. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002; 34:1613-20.
3. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33:2759-62.
4. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270:1826-31.
5. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
6. Karma P, Pukander J, Sipila M, et al. Prevention of otitis media in children by pneumococcal vaccination. Am J Otolaryngol 1985; 6:173-84.
7. Temple K, Greenwood B, Inskip H, Hall A, Koskela M, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 1991; 10:386-90.
8. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
9. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9.
10. Vakevainen M, Jansen W, Saeland E, et al. Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Clin Diagn Lab Immunol 2001; 8:363-9.
11. Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000; 181:1162-6.
12. Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 2001; 183:253-60.
13. Saeland E, Vidarsson G, Jonsdottir I. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 2000; 29:81-91.
14. Jakobsen H, Saeland E, Gizurarson S, Schulz D, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 1999; 67:4128-33.
15. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999; 67:5892-7.
16. Vidarsson G, van de Winkel JGJ. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis 1998; 11:271-8.
17. Deo YM, Graziano RF, Repp R, van de Winkel JGJ. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 1997; 18:127-35.
18. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90.
19. Ravetch JV. Fc receptors: rubor redux. Cell 1994; 78:553-60.
20. Ra C, Jouvin MH, Blank U, Kinet JP. A macrophage Fcγ receptor and the mast cell receptor for IgE share an identical subunit. Nature 1989; 341:752-4.
21. Hibbs ML, Selvaraj P, Carpen O, et al. Mechanisms for regulating expression of membrane isoforms of FcγRIII (CD16). Science 1989; 246:1608-11.
22. van Vugt MJ, Heijnen AF, Capel PJ, et al. FcR γ-chain is essential for both surface expression and function of human Fc γ RI (CD64) in vivo. Blood 1996; 87:3593-9.
23. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 1994; 76:519-29.
24. Park SY, Ueda S, Ohno H, et al. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest 1998; 102:1229-38.
25. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fcγ RII-deficient mice. Nature 1996; 379:346-9.
26. Nakamura A, Yuasa T, Ujike A, et al. Fcγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 2000; 191:899-906.
27. Fossati-Jimack L, Reininger L, Chicheportiche Y, et al. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med 1999; 190:1689-96.
28. Hazenbos WL, Heijnen IA, Meyer D, et al. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CD16). J Immunol 1998; 161:3026-32.
29. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002; 16:391-402.
30. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981; 11:1012-6.
31. Coxon A, Rieu P, Barkalow FJ, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 1996; 5:653-66.
32. Hazenbos WL, Gessner JE, Hofhuis FM, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity 1996; 5:181-8.
33. Jakobsen H, Adarna BC, Schulz D, Rappuoli R, Jonsdottir I. Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization. J Infect Dis 2001; 183:1494-500.
34. Younger JG, Sasaki N, Delgado J, et al. Systemic and lung physiological changes in rats after intravascular activation of complement. J Appl Physiol 2001; 90:2289-95.
35. Klerx JP, Beukelman CJ, van Dijk H, Willers JM. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods 1983; 63:215-20.
36. Jones B, Tite JP, Janeway CA, Jr. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. J Immunol 1986; 136:348-56.
37. Mellman IS, Unkeless JC. Purificaton of a functional mouse Fc receptor through the use of a monoclonal antibody. J Exp Med 1980; 152:1048-69.
38. Rodriguez ME, van der Pol WL, van de Winkel JGJ. Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. J Immunol Methods 2001; 252:33-44.
39. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990; 75:1037-50.
40. Rodrigues, van der Pol WL, Sanders LA, Verheul AF, van de Winkel JGJ. Crucial role of FcγRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J Infect Dis 1999; 179:423-33.
41. Sanders LA, van de Winkel JGJ, Rijkers GT, et al. Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170:854-61.
42. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcγRIIa-R131 allotype and bacteremic pneumococal pneumonia. Clin Infect Dis 2000; 30:25-8.
43. Regnault A, Lankar D, Lacabanne V, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:371-80.
44. Amigorena S, Lankar D, Briken V, Gapin L, Viguier M, Bonnerot C. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J Exp Med 1998; 187:505-15.
45. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195:1653-9.
46. Hamano Y, Arase H, Saisho H, Saito T. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol 2000; 164:6113-9.
47. McLay J, Leonard E, Petersen S, Shapiro D, Greenspan NS, Schreiber JR. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J Immunol 2002; 168:3437-43.
48. Hostetter MK. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis 1986; 153:682-93.
49. Joiner K, Brown E, Hammer C, Warren K, Frank M. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing. J Immunol 1983; 130:845-9.
50. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 1996; 383:263-6.
51. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13:277-85.